Adamas Announces US FDA Acceptance of ADS-5102 New Drug Application for the Treatment of Levodopa-induced Dyskinesia in Patients with PD

(January 6, 2017) - Adamas Pharmaceuticals announced that the U.S. Food and Drug Administration has accepted for review the New Drug Application for ADS-5102 (amantadine hydrochloride) extended-release capsules, for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson's disease. If approved, ADS-5102 will be the first and only medicine approved for the treatment of LID in Parkinson’s disease. Read more